METHOD FOR PRODUCING GENETICALLY EDITED BIRDS HAVING RESISTANCE TO AVIAN INFLUENZA VIRUSES
20220380797 · 2022-12-01
Inventors
- Jae Yong Han (Seoul, KR)
- Young Hyun PARK (Seoul, KR)
- Jeong Yong SUH (Seoul, KR)
- Jeong Mook LIM (Gyeonggi-do, KR)
Cpc classification
C12N2310/20
CHEMISTRY; METALLURGY
A01K67/0275
HUMAN NECESSITIES
C12N9/22
CHEMISTRY; METALLURGY
C12N15/8509
CHEMISTRY; METALLURGY
C12N2800/80
CHEMISTRY; METALLURGY
C12N15/11
CHEMISTRY; METALLURGY
C12N15/113
CHEMISTRY; METALLURGY
C12N15/90
CHEMISTRY; METALLURGY
International classification
C12N15/11
CHEMISTRY; METALLURGY
Abstract
Provided is a method of producing a genome-edited bird having resistance to avian influenza viruses. A method according to an aspect may enable precise inhibition of interaction between virus proteins while maintaining the original function of an ANP32A gene in a host by substituting only key amino acids of the ANP32A gene. When the method is used, by including cell lines having resistance to avian influenza viruses, new poultry and bird breeds that may not pose any biological safety issues may be efficiently developed. Thus, it is expected that the potential for industrial application is high.
Claims
1. A recombinant vector comprising a guide RNA (gRNA) or a polynucleotide encoding the gRNA, wherein the guide RNA (gRNA) targets at least one residue selected from the group consisting of Asp149, Asp152, Asp182, and Asp185 in an Acidic Nuclear Phosphoprotein 32 Family Member A (ANP32A) gene.
2. The recombinant vector of claim 1, wherein the gRNA is represented by SEQ ID NO: 14.
3. The recombinant vector of claim 1, wherein the polynucleotide comprises a protospacer adjacent motif (PAM).
4. A genome-editing composition comprising the recombinant vector of claim 1 and at least one nuclease encoding sequence selected from the group consisting of CRISPR associated protein 9 (Cas9), CRISPR from Prevotella and Francisella 1 (Cpf1), a transcription activator-like effector nuclease (TALEN), and a zinc finger nuclease (ZFN).
5. The genome-editing composition of claim 4, wherein the genome-editing composition induces substitution of at least one selected from the group consisting of D149Y, D152H, D182Y, and D185H in an ANP32A gene.
6. The genome-editing composition of claim 4, wherein the composition is for inducing resistance to avian influenza viruses.
7. A transformed cell into which the recombinant vector of claim 1 is introduced.
8. The transformed cell of claim 7, wherein the cell is selected from the group consisting of stem cells, somatic cells, germ cells, fertilized eggs, and embryos, of a bird.
9. The transformed cell of claim 8, wherein the germ cells are primordial germ cells (PGCs).
10. The transformed cell of claim 7, wherein the transformed cell is a cell in which at least one residue selected from the group consisting of Asp149, Asp152, Asp182, and Asp185 in an ANP32A gene is substituted.
11. A method of producing a transformed cell, the method comprising introducing the recombinant vector of claim 1 or the genome-editing composition of claim 4 into a bird somatic cell.
12. A method of producing a genome-edited bird comprising transplanting the transformed cell of claim 7 into an embryo of a bird.
13. The method of claim 12, wherein the bird is selected from the group consisting of chickens, ducks, geese, quails, pheasants, and turkeys.
14. The method of claim 12, wherein the genome-edited bird has resistance to avian influenza viruses.
15. A genome-edited bird having resistance to avian influenza viruses, produced according to the method of claim 12.
16. A transformed cell into which the genome-editing composition of claim 4 is introduced.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
DETAILED DESCRIPTION
[0061] Hereinafter, the present disclosure will be described in more detail with reference to Examples. However, these Examples are for illustrative purposes only, and the present disclosure is not intended to be limited by these Examples.
Experiment Method
Sequence analysis of ANP32 family gene
[0062] To find key genes involved in proliferation of avian influenza viruses, human and chicken ANP32 family genes (ANP32A, ANP32B, ANP32C, ANP32D, and ANP32E) were analyzed. In particular, sequence information of cANP32A (XP_413932), cANP32B (NP_001026105), cANP32E (NP_001006564), hANP32A (NP_006296), hANP32B (NP_006392), hANP32C (NP_036535), hANP11232D (NP_036536), and hANP32D (NP_036536) provided from NCBI database was obtained. Then, pairwise sequence alignment and multiple sequence alignment analysis were performed. The protein sequences were aligned by using Geneious R6 software (Biomatters Ltd., Auckland, New Zealand) using Blosum62 scoring matrix, and 12 gap open penalty and 3 gap extension penalty were used.
Production of Recombinant Avian Influenza Viruses
[0063] Recombinant avian influenza viruses PR8-H5N8 PB2-627E and -627K were produced using reverse genetics approach from 8 bidirectional PHW2000 plasm ids in the same method as in the previous study (Park et al., J Infect Dis, 2019). Briefly, 8 bidirectional plasmids were co-transfected with co-cultured Madin-Darby canine kidney cells (MDCK; ATCC, CCL-34) and human 293T embryonic kidney cells (HEK293T; ATCC, CRL-11268) to obtain virus. The obtained virus was grown in MDCK infection medium consisting of DMEM supplemented with 0.3% bovine serum albumin (BSA), 1x ABAM, and 1 μg/mL TPCK-treated trypsin (Sigma-Aldrich, MO, USA), and then the obtained virus was cultured for 48 hours at 37° C. The virus stock was further propagated in 10-day-old incubated eggs, and an aliquot of the infectious virus was stored at −80° C. for further experiments.
Virus Titration
[0064] TCID.sub.50 was determined by performing virus titration of infected cells in MDCK cells. Briefly, a confluent layer of MDCK cells cultured in serum-free DMEM supplemented with 0.3% BSA, 1% penicillin/streptomycin, and 1 μg/mL TPCK-trypsin in 96-well plates, i.e., a supernatant of the infected cells was used for infection. Serial dilutions of the supernatant were added in triplicate to 5 wells of a 96-well plate. After 72 hours to 96 hours, the cell denaturation effect was observed and quantified through crystal violet (Sigma-Aldrich) staining. The TCID.sub.50per mL was calculated using Spearman-Karber formula (Gilles, Eur J Toxicol Environ Hyg, 1974).
RT-qPCR
[0065] Total RNA was extracted using RNeasy mini kit (Qiagen), and reverse transcription was performed using Superscript IV First-strand Synthesis System (Thermo Fisher Scientific). RT-qPCR based on EvaGreen qPCR dye (Biotium, CA, USA) was performed three times using the StepOnePlus real-time PCR system (Thermo Fisher Scientific). The target gene-specific forward and reverse primers are shown in Table 1. Relative quantification of target gene expression was calculated using the 2-AAct formula (here, .sup.ΔΔCt=(Ct of target gene - Ct of ACTB) group - (Ct of target gene - Ct of ACTB) control.
Co-Immunoprecipitation
[0066] Total protein was prepared from cell lysates of transfected cells using immunoprecipitation lysis buffer (Thermo Fisher Scientific). For immunoprecipitation, target antibody-conjugated magnetic beads were prepared using Dynabeads Protein G kit (Thermo Fisher Scientific) according to the manufacturer's instructions. Briefly, non-specific binding proteins were removed in advance by incubating with unbound magnetic beads with gentle rotation at 4° C. for 30 minutes. Then, the previously removed cell lysate was cultured with target antibody-conjugated magnetic beads at 4° C. overnight while gently rotating. Magnetic beads were collected using a magnetic field, and then washed 4 times for unbound protein with a wash buffer. The immunoprecipitated protein was eluted for 5 minutes using an elution buffer and denatured at 95° C. for 5 minutes using 2×Laemmli sample buffer (BioRad). Magnetic beads were collected using a magnetic field, and then the supernatant was used for subsequent experiments.
Western Blotting
[0067] The total protein or immunoprecipitated protein was separated by 10% SDS-PAGE. The separated protein was transferred to a PVDF membrane and blocked for 1 hour. The membrane was incubated with an appropriate primary antibody and then incubated with an appropriate HRP-conjugated secondary antibody (Thermo Fisher Scientific). The antibodies used in the experiment are as follows: anti-ACTB (sc-47778, Santa Cruz, TX, USA), anti-ANP32A (sc-100767, Santa Cruz), anti-FLAG (F1804, Sigma-Aldrich), anti-PA (GTX125932, GeneTex, CA, USA), anti-PB1 (GTX125923, GeneTex), anti-PB2 (GTX125926, GeneTex), and anti-NP (GTX125989, GeneTex). Immunoreactive proteins were visualized using ECL select Western blotting detection reagent (GE Healthcare Bio-Sciences, NJ, USA), and signals were detected using BioRad ChemiDoc XRS imaging system (BioRad, CA, USA).
Statistical Analysis
[0068] For statistical analysis, GraphPad Prism (GraphPad Software, CA, USA) was used. Significance between groups was determined through one-way ANOVA analysis using Bonferni's multiple comparisons. P<0.05 indicates statistical significance.
Experimental Results
Example 1. Sequence Analysis of ANP32 Family Gene
[0069] As compared with human ANP32A (hANP32A), chicken ANP32A (cANP32A) contains additional amino acid residues 176 to 208, which are duplicated from amino acid residues 149 to 175 (27 residues). However, the functional role of the 27 amino acid residues of hANP32A has not yet been studied. Therefore, based on the comparison between hANP32A family members, it was attempted to find key amino acid residues contributing to viral polymerase activity through modification of 27 residues. As a result of investigating the sequence identity of the amino acid residues 149-175 of hANP32 family members through pairwise sequence alignment, it was found that the percent of identity of hANP32A with hANP32B, hANP32C, hANP32D, and hANP32E was approximately 68.3%, 86.1%, 89.3% and 56.6%, respectively. Next, as a result of investigating the sequence identity of N-terminal leucine rich repeat (LRR) and C-terminal low complexity acidic region (LCAR) domain through pairwise sequence alignment, it was found that the percent of identity of LRR and LCAR domains of hANP32A with LRR and LCAR domains of hANP32B, hANP32C, hANP32D, and hANP32E was 81.1%, 87.2%, 89.3%, and 71.6%, respectively. In the LCAR domain, the percent of identity of hANP32A with hANP32B, hANP32C, and hANP32E was about 4.7%, 84.4%, and 43.7%, respectively (hANP32D was excepted because the LCAR domain is not present in hANP32D).
Example 2. Construction of Recombinant Vector Targeting cANP32A Through CRISPR/Cas9 System
[0070] A CRISPR/Cas9 vector targeting the cANP32A gene was produced using a pX459 vector in the same method as in the previous study (Lee et al., Dev Comp Immunol, 2017). The sequences of all oligonucleotides used for PCR analysis and CRISPR/Cas9 vector production are shown in Table 1.
TABLE-US-00002 TABLE 1 Sequence ID Sequence (5′-3′) Use ID No. ANP32A ex1-F CACCGGCGACGATGGACGGGACGAG Sequencing 5 ANP32A ex1-R AAACCTCGTCCCGTCCATCGTCGCC Sequencing 6 ANP32A ex4/5-F CTGTCTGTCCTGTAGAGGTTTA Sequencing 7 ANP32A ex4/5-R GTCTTCCTCCTTCCAGTCTCT Sequencing 8 ACTB qRT-F AGGAGATCACAGCCCTGGCA RT-qPCR 9 ACTB qRT-R CAATGGAGG GTCCGG ATTCA RT-qPCR 10 viral M qRT-F AACCGAGGTCGAAACGTACG RT-qPCR 11 viral M qRT-R CGGTGAGCGTGA ACACAAAT RT-qPCR 12 A#1 gRNA AAAGGATCCACTTAGAGCTG gRNA 13 sequence A#4 gRNA CCACAACTCACATACCTCGA gRNA 14 sequence
[0071] Briefly, the annealed oligonucleotide for each gRNA was ligated to the pX459 vector through the Golden Gate assembly method, and the prepared CRISPR/Cas9 vector was analyzed through Sanger sequencing. For homology directed repair (HDR)-mediated precise gene editing of cANP32A, double-cut donor-mediated HDR was performed using a donor plasmid (Bionics, Seoul, Korea) in the same method as in the previous study (Park et al., J Infect Dis, 2019). The HDR donor plasm id for amino acid residue substitution of D149Y, D152H, D182Y, and D185H is a target genetic locus with two gRNA-PAM sequences on flanking, and 400 bp of homology arms on the right and left are included. The gRNA sequence targeting cANP32A exon 4 (A#4) between the homology arms of the donor plasmid on right and left was modified to prevent further cleavage after HDR.
Example 3. Transfection of Fibroblast Cells Using Recombinant Vector
[0072] The CRISPR/Cas9 recombinant vector produced in Example 2 was mixed with Lipofectamine 2000 reagent (Thermo Fisher-Invitrogen) in Opti-MEM (Thermo Fisher-Invitrogen), and the mixture was introduced and transfected to chicken fibroblast cell line DF-1 (CRL-12203; ATCC, VA, USA). DF-1 used at this time was maintained in DMEM (Hyclone, Logan, Utah, USA) medium to which 10% fetal bovine serum (FBS; Hyclone) and 1x antibiotic-antimycotic (ABAM; Thermo Fisher-Invitrogen, Carlsbad, Calif., USA) were added. After transfection, puromycin (Thermo Fisher Scientific) was added to the culture medium for 4 days to select transfected cells. The puromycin-selected single DF-1 cells were inoculated into individual wells of a 96-well plate. After clonal expansion of each single DF-1 cell, genomic DNA was extracted from the clone and used for sequence analysis.
Example 4. T7E1 Analysis and Genome DNA Sequence Analysis
[0073] To evaluate the target efficiency of CRISPR/Cas9 in the transfected DF-1 cells produced in Example 3, T7 endonuclease 1 (T7E1) analysis was performed. The primer sets used for amplification of the genomic region including the CRISPR/Cas9 target site are shown in Table 1. To form heteroduplex DNA, amplicons were reannealed after denaturation, and the reannealed heteroduplex amplicons were digested with T7E1 (New England Biolabs) enzyme at 37° C. for 20 minutes. The product digested with T7E1 was analyzed by 1 agarose gel electrophoresis. For sequence analysis, the PCR product containing the target site was cloned into pGEM-T Easy vector (Promega, WI, USA), followed by sequencing using an ABI Prism 3730 XL DNA analyzer (Thermo Fisher-Applied Biosystems, CA, USA). For sequence analysis, BLAST (http://blast.ncbi.nlm.nih.gov) and Geneious R6 software (Biomatters Ltd.) were used.
[0074] Specifically, the CRISPR/Cas9 vector targeting exon 1 of cANP32A (A#1 vector) was prepared to investigate whether hANP32 family members may be involved in replication of avian influenza in cANP32A-knockout DF-1 cells (A_KO) (
Example 5. Functional Effects of ANP32 Family and Effects of ANP32 Mutations on vPol Activity
[0075] In order to identify whether mutations induced at residues 149 to 175 in an ANP32 protein may affect viral polymerase (vPol) activity of avian influenza, an overexpression vector carrying the cANP32A or codon-optimized hANP32A, hANP32C, or hANP32E sequence expressed by a cytomegalovirus (CMV) promoter was constructed in the same method as in the previous study (Park et al., J Infect Dis, 2019). Modification or gene swapping experiments of residues 149 to 175 of ANP32 protein were performed using a Q5 site-directed mutagenesis kit (New England Biolabs, MA, USA). All plasmid constructs were verified by DNA sequencing. For transient expression of the modified ANP32 protein, the constructed vector was transfected into DF-1 cells using Lipofectamine 2000 reagent (Thermo Fisher-Invitrogen). After 48 hours of transfection, expression of hANP32 protein in A_KO cells was verified by Western blot (
[0076] As a result, it was confirmed that hANP32C, hANP32D, or hANP32E overexpression did not contribute to virus replication, whereas hANP32A and hANP32B expression enabled virus replication in A_KO cells regardless of PB2-627 residue (
[0077] Next, to analyze functional significance of 27 residues for vPol activity, residues 149 to 175 of human and chicken ANP32 proteins were aligned. As a result, it was confirmed that the sequence identity of the 27 residues varied from 48.1% to 100% in the ANP32 family members of human and chicken. Specifically, the sequence identities between cANP32A and hANP32A, cANP32B, hANP32B, hANP32C, cANP32E, and hANP32E were 100%, 51.9%, 70.4%, 66.7%, 48.1%, and 48.1%, respectively (
[0078] In this regard, an analysis was performed to identify whether different residues between hANP32A and hANP32C have a differential role in vPol activity and virus replication. First, a vector from which residues 149 to 175 of hANP32A were removed (hANP32A27del), a vector from which residues 149 to 175 of hANP32A were replaced with residues 149 to 175 of hANP32C (hANP32A27C), a vector from which residues 149 to 175 of hANP32C were replaced with residues 149 to 175 of hANP32A (hANP32C27A), or a vector from which residues 149 to 175 of hANP32E were replaced with residues 149 to 175 of hANP32A (hANP32E27A) was constructed. After transfecting the constructed vectors into A_KO cells, the cells were infected with H5N8-627E, and the expression level of the virus gene was analyzed using RT-qPCR. As a result, it was confirmed that overexpression of hANP32A27del, hANP32A27C, hANP32C, hANP32E, or hANP32E27A did not contribute to virus gene transcription, whereas overexpression of control hANP32A or hANP32C27A could contribute to virus gene transcription in A_KO cells. In particular, for hANP32C, it was shown that the vector (hANP32C27A) in which 27 residues of hANP32A were replaced may contribute to vPol activity, but hANP32E27A did not contribute to vPol activity. It was found that the remaining domains LRR and LCAR are also essential to vPol activity, in addition to the 27 residues (
Example 6. Identification of Key Amino Acids of ANP32A Involved in vPol Activity
[0079] In order to identify key amino acid residues among the 27 residues involved in vPol activity and virus proliferation, the ANP32A sequence was mutated. First, hANP32A residues 149 to 161 and 162 to 175 residues were replaced with 149 to 161C and 162 to 175C regions of hANP32C, respectively, to produce h32A (
[0080] Next, through pairwise sequence comparison between hANP32C and hANP32A including D149Y, R150A, D152H, D156Y, and A161I substitutions, it was investigated whether single residue substitution may inhibit AIV replication. As a result, it was confirmed that substitution of D149Y and D152H in hANP32A significantly reduced the transcription level of the virus gene. From the results, Asp149 (D149) and Asp152 (D152) were found to be key amino acid residues involved in vPol activity and virus proliferation. Additionally, as a result of overexpressing hANP32B-modified protein in A_KO cells and analyzing the virus titer, it was confirmed that D149Y and D152H substitution (hANP32BD149Y/D152H) in hANP32B significantly reduced the virus titer of AIV, as compared with overexpression of wild-type hANP32B (
[0081] To confirm whether the functional roles of D149 and D152 are conserved in both hANP32A and hANP32B, pairwise sequence alignment of residues 149 to 161 was performed. As a result, it was confirmed that D149 and D152 were conserved in both hANP32A and hANP32B (
Example 7. Effect of Protein Interaction on vPol Activity
[0082] In consideration of a significant polarity difference at amino acid residues 149 and 152 between hANP32A and hANP32C, polarity mapping by the Geneious Program was used to focus on the polarity and charge of the residue to determine which molecular interactions were involved in the residue. (
[0083] In order to confirm whether the mutation of the identified residue affects the protein interaction between ANP32A and vPol protein, additional immunoprecipitation analysis was performed. Specifically, the interaction between wild-type or mutant hANP32A and vPol protein in A_KO DF-1 clone was analyzed. As a result, viral PA and PB2 proteins were co-immunoprecipitated with wild-type hANP32A (hANP32Awt). On the other hand, it was confirmed that the hANP32AD149Y/D152H mutant exhibited reduced interaction with virus protein after anti-FLAG co-immunoprecipitation regardless of residue PB2-627 (
Example 8. Precise Gene Editing for Chicken ANP32A
[0084] By using the CRISPR/Cas9 system, it was confirmed that precise substitution of amino acid residues for chicken ANP32A via homologous recombination significantly reduced virus replication in chicken cells. First, to target exon 4 of the cANP32A gene, DF-1 cells were transfected with CRISPR/Cas9 vector containing A#4 gRNA sequence, and it was confirmed that target efficiency was performed by T7E1 analysis and genomic DNA sequencing of transfected DF-1 cells. (
[0085] Because cANP32A has additionally cloned D182 and D185 residues, D149Y, D152H, D182Y, and D185H (A.sub.YHYH ) modifications were induced for the cANP32A gene using a double cut-mediated HDR system in the method as in the previous study (Zhang et al., Genome Biol, 2017; Park et al., J Infect Dis, 2019) (
[0086] Next, a DF-1 clone was established through single cell clone expansion of the transfected cell, and as a result of performing cDNA sequencing on the established clone, a clone (A.sub.YHYH 106) in which the target sequence was precisely substituted was confirmed (
[0087] In order to evaluate the exact modification effect of cANP32A residue in DF-1, established cell clones including A.sub.YHYH 101 (premature stop codon), A.sub.YHYH 103 (wild-type), and A.sub.YHYH 106 (HDR) were used with MOI 0.1 PR8-H5N8 LPAI (PB2-627E or PB2-627K). As a result, it was confirmed that the virus titer in both A.sub.YHYH 101 and A.sub.YHYH 106 clones was significantly lower than in A.sub.YHYH103 clone regardless of residue PB2-627 (
[0088] Through the results, it was confirmed that the method according to one aspect may acquire resistance to avian influenza viruses (AIV) by inducing mutations in an ANP32A, which is involved in virus replication in host cells. In particular, by modifying only the key amino acid residue of ANP32A, it was confirmed that resistance to AIV may be acquired by precisely limiting only the interaction in the relationship with the AIV protein while maintaining the original function of the ANP32A gene. Therefore, the method according to one aspect may be widely applied to disease-resistant cell lines, disease-resistant poultry, and animal production.
[0089] As described above, specific parts of the present invention have been described in detail, and it will be apparent to of ordinary skill in the art that this specific description is only a preferred embodiment, and the scope of the present invention is not limited thereto. Accordingly, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.